Adagio Medical Holdings Inc: RA Capital Management Acquires 1.2M Shares

Ra Capital Management, a Boston-based investment firm, acquired 1.2 million shares of Adagio Medical Holdings Inc at $1.30 per share, marking a 0.03% position in its overall holdings and a 7.20% stake in Adagio Medical's total shares. The firm focuses on healthcare and financial services sectors and has established itself as a key player in the investment landscape. Adagio Medical Holdings Inc specializes in catheter ablation technologies for cardiac arrhythmias and has shown promise in its niche despite facing financial challenges.

RA Capital Management, a Boston-based investment firm, has acquired 1.2 million shares of Adagio Medical Holdings Inc. at a price of $1.30 per share, marking a 0.03% position in its overall holdings and a 7.20% stake in Adagio Medical's total shares. This acquisition was announced through an amendment to Schedule 13G, filed with the Securities and Exchange Commission (SEC) [1].

Adagio Medical Holdings Inc specializes in catheter ablation technologies for cardiac arrhythmias. Despite facing financial challenges, the company has shown promise in its niche. RA Capital Management focuses on healthcare and financial services sectors and has established itself as a key player in the investment landscape.

The filing clarifies that 1,140,000 of the acquired shares are issuable upon exercise of warrants held directly by RA Capital Healthcare Fund, L.P., and 60,000 shares are issuable upon exercise of warrants held by RA Capital Nexus Fund II, L.P. RA Capital, Dr. Kolchinsky, and Mr. Shah note delegated voting and dispositive powers for the funds and file this amendment to correct a prior clerical omission of the warrant-based holdings [1].

This disclosure matters because holdings above 5% generally attract investor attention and regulatory reporting obligations. The amendment corrects a clerical omission, improving transparency about contingent common shares from warrants that are immediately exercisable. There is no indication in the filing that the holders seek to influence control; the report maintains disclaimers and delegated voting arrangements [1].

From a governance perspective, stakeholders should note the reported stake passes the 5% notification threshold and that the filers expressly disclaim group status and any current intent to influence control. The filing clarifies beneficial ownership attributable to warrants and reconfirms delegated voting/dispositive authority to the adviser. That structure is common for investment-manager relationships but the previous omission of warrant-derived shares is a disclosure lapse that was remedied [1].

References:
[1] https://www.stocktitan.net/sec-filings/ADGM/schedule-13g-a-adagio-medical-holdings-inc-sec-filing-352b858cb0a1.html